The market for Graves' ophthalmopathy is projected to expand at a strong pace between 2026 and 2036, with DelveInsight highlighting a compound annual growth rate of about 9%. The report points to growing demand for treatment as more patients are identified earlier and awareness of the condition continues to improve.
A key factor in that outlook is the recent approval of Viridian's LUMVOA, which adds fresh momentum to the treatment landscape. New product entries and other emerging therapies are expected to reshape care options for patients with Graves' ophthalmopathy, a condition linked to autoimmune thyroid disease.
The growth outlook is also supported by the broader rise in autoimmune thyroid disorders, which can increase the number of people needing evaluation and treatment for eye-related complications. Better recognition of symptoms and faster diagnosis may further expand the addressable patient population over the forecast period.
Overall, the report suggests that innovation in therapy, along with stronger disease awareness, could drive meaningful market gains over the next decade. As additional treatments reach patients, the Graves' ophthalmopathy space appears positioned for continued development.
